TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2891372

Group type: EXPERIMENTAL
Intervention: 16-phenoxy-W-17, 18, 19, 20-tetranor PGE2 methyl sulfonylamide (three intramuscular injections of 0.5 mg at 3-h intervals)
Number of subjects: 473

Group type: COMPARATOR
Intervention: Vacuum aspiration
Number of subjects: 473
Study: 29395279

Group type: EXPERIMENTAL
Intervention: OTO‐201 (ciprofloxacin otic suspension 6%) intraoperative injection
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Medicaid patients
Number of subjects: 501

Group type: COMPARATOR
Intervention: Previous Phase 3 trials
Number of subjects: 501
Study: 28629473

Group type: COMPARATOR
Intervention: Intravenous phenytoin (20 mg/kg, maximum 2 g)
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Intravenous levetiracetam (40 mg/kg, maximum 2.5 g)
Number of subjects: 308
Study: 26332900

Group type: COMPARATOR
Intervention: Chlorhexidine-containing mouthwash (STRONG)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Non-chlorhexidine mouthwash (WEAK)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Deionised water (CON)
Number of subjects: 12
Study: 23300238

Group type: EXPERIMENTAL
Intervention: 7-day antiretroviral regimen (zidovudine/lamivudine, tenofovir/emtricitabine, or lopinavir/ritonavir)
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: 21-day antiretroviral regimen (zidovudine/lamivudine, tenofovir/emtricitabine, or lopinavir/ritonavir)
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 484
Study: 20921467

Group type: EXPERIMENTAL
Intervention: Concurrent therapy (paclitaxel 225 mg/m² and carboplatin AUC 6 every 3 weeks plus cetuximab 400 mg/m² loading dose followed by 250 mg/m² weekly for four cycles)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Sequential therapy (paclitaxel-carboplatin for four cycles followed by cetuximab)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 224
Study: 19099714

Group type: EXPERIMENTAL
Intervention: Inhaled Nitric Oxide (iNO) at 15 ppm for 34.90 ± 16.41 hours
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (no iNO)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Inhaled Nitric Oxide (iNO)
Number of subjects: 46
Study: 17213687

Group type: EXPERIMENTAL
Intervention: Short-term air-conditioning exposure (S)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-term air-conditioning exposure (L)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 0
Study: 12648193

Group type: EXPERIMENTAL
Intervention: Music (M)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Music in combination with therapeutic suggestions (M/TS)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Control (blank tape)
Number of subjects: 182
Study: 10922094

Group type: EXPERIMENTAL
Intervention: Oral preparation (45 mL oral sodium phosphate and 10 mg bisacodyl)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Enema preparation (2 Fleet enemas and 10 mg bisacodyl)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Oral preparation
Number of subjects: 250

Group type: COMPARATOR
Intervention: Enema preparation
Number of subjects: 250
Study: 8756233

Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 50
Study: 8141211

Group type: EXPERIMENTAL
Intervention: Amoxicillin (500 mg three times daily for 7 days)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Erythromycin (500 mg four times daily for 7 days)
Number of subjects: 74
Study: 3410567

Group type: EXPERIMENTAL
Intervention: Dialysate temperature at 35 degrees C
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Sodium concentration at 139 mmol/l
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Polyacrylonitrile membrane
Number of subjects: 8

Group type: COMPARATOR
Intervention: Cuprophan membrane
Number of subjects: 8
Study: 29613950

Group type: EXPERIMENTAL
Intervention: Blood donation (whole blood donation)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Mock donation (control group)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Cognitive tests (three tests)
Number of subjects: 57
Study: 28929582

Group type: EXPERIMENTAL
Intervention: Psychoeducation intervention via WhatsApp (1 face-to-face session of 60 min and 4 virtual sessions of 30 min each)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Psychoeducation intervention via WhatsApp
Number of subjects: 62
Study: 26047059

Group type: EXPERIMENTAL
Intervention: Modified dot-probe protocol
Number of subjects: 108

Group type: COMPARATOR
Intervention: Standard dot-probe protocol (control)
Number of subjects: 108
Study: 24244435

Group type: EXPERIMENTAL
Intervention: Menstrual experiences of young adolescent schoolgirls
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Menstrual hygiene practices
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: School attendance during menstruation
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Emotional and physical support mechanisms
Number of subjects: 120
Study: 21148631

Group type: EXPERIMENTAL
Intervention: Sodium oxybate (SXB) 3 g per night for five consecutive nights
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (matched controls)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Sodium oxybate (SXB)
Number of subjects: 16
Study: 18240042

Group type: EXPERIMENTAL
Intervention: Regular exercise group with self-initiated training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intensive exercise group with scheduled intensive training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physical mobility sub-scale of NHP
Number of subjects: 0
Study: 16816220

Group type: EXPERIMENTAL
Intervention: Mirtazapine (up to 60 mg/day)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Nortriptyline (up to 200 mg/day)
Number of subjects: 235
Study: 12705063

Group type: EXPERIMENTAL
Intervention: Selective cyclooxygenase‐2 inhibitor (celexocib)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non steroidal anti‐inflammatory drugs (NSAIDs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin®
Number of subjects: 0
Study: 10831483

Group type: EXPERIMENTAL
Intervention: Sertraline (50-200 mg)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 8527613

Group type: EXPERIMENTAL
Intervention: etodolac 300 mg b.d.
Number of subjects: 24

Group type: COMPARATOR
Intervention: naproxen 500 mg b.d.
Number of subjects: 24
Study: 2175569

Group type: EXPERIMENTAL
Intervention: Dietary vitamin E supplementation for 48 days before exercise
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 6250823

Group type: EXPERIMENTAL
Intervention: Noise exposure (intermittent noise alternating between 99 dB (A) and 45 dB (A) for 2 hours)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Noise exposure
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (no noise exposure)
Number of subjects: 7
Study: 31107542

Group type: EXPERIMENTAL
Intervention: Dose‐intensified radiotherapy plus capecitabine and oxaliplatin (CAPOX50)
Number of subjects: 316

Group type: COMPARATOR
Intervention: Preoperative radiotherapy plus capecitabine (CAP45)
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 316
Study: 28002167

Group type: EXPERIMENTAL
Intervention: Haloperidol 1 mg intravenously
Number of subjects: 120

Group type: COMPARATOR
Intervention: Ondansetron 4 mg intravenously
Number of subjects: 120
Study: 26226960

Group type: EXPERIMENTAL
Intervention: PQQ disodium salt (BioPQQ™) at an oral dosage of 20 mg/d for 12 weeks
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: PQQ disodium salt (BioPQQ™) in high LDL-chol subgroup (baseline LDL-chol ≥140 mg/dL)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 24013586

Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combined strength and endurance training
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Strength training alone
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study: 20593204

Group type: EXPERIMENTAL
Intervention: Trunk flexor and general strength (TFS) training
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Specific motor control (SMC) training
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 24
Study: 20077733

Group type: EXPERIMENTAL
Intervention: JEV‐I (PHK) vaccine
Number of subjects: 943

Group type: COMPARATOR
Intervention: Control vaccine (Vero cell-derived JEV vaccine)
Number of subjects: 943
Study: 17275282

Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg and droperidol 0.625 mg (combination)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Droperidol 1.25 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: COMPARATOR
Intervention: Dexamethasone 4 mg
Number of subjects: 120
Study: 15150184

Group type: EXPERIMENTAL
Intervention: Ertapenem, 1 g once a day
Number of subjects: 866

Group type: COMPARATOR
Intervention: Ceftriaxone, 1 g once a day
Number of subjects: 866
Study: 11464117

Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: TENS + Ondansetron
Number of subjects: 25
Study: 9664225

Group type: EXPERIMENTAL
Intervention: Stimulus probabilities (0.90/0.10, 0.80/0.20, 0.70/0.30, 0.60/0.40, 0.50/0.50 alternation, 0.50/0.50 random)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Stimulus probabilities
Number of subjects: 6
Study: 8529737

Group type: EXPERIMENTAL
Intervention: Alphuzosine
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Terazosine
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 2913182

Group type: EXPERIMENTAL
Intervention: Internal Medicine Clinic
Number of subjects: 520

Group type: COMPARATOR
Intervention: Family Practice Clinic
Number of subjects: 520
Study: 765292

Group type: EXPERIMENTAL
Intervention: Maprotiline
Number of subjects: 30

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 30
Study: 31279073

Group type: EXPERIMENTAL
Intervention: D/C/F/TAF (800/150/200/10 mg)
Number of subjects: 1141

Group type: EXPERIMENTAL
Intervention: Late-switch to D/C/F/TAF (after 44 weeks of F/TDF)
Number of subjects: 1141

Group type: COMPARATOR
Intervention: Boosted PI plus emtricitabine/tenofovir-disoproxil-fumarate (F/TDF)
Number of subjects: 1141
Study: 28713645

Group type: EXPERIMENTAL
Intervention: Test agent (novel slowly dissolving adhering disc) plus oral hygiene self-care
Number of subjects: 5

Group type: COMPARATOR
Intervention: Oral hygiene self-care only
Number of subjects: 5
Study: 25733627

Group type: EXPERIMENTAL
Intervention: Sodium intake <2300 mg/d
Number of subjects: 3982

Group type: EXPERIMENTAL
Intervention: Increasing sodium intake >2300 mg/d
Number of subjects: 3982

Group type: COMPARATOR
Intervention: MedDiet interventions with reduced sodium intake
Number of subjects: 3982
Study: 22850357

Group type: EXPERIMENTAL
Intervention: Participants aged 55-65 years
Number of subjects: 13946

Group type: EXPERIMENTAL
Intervention: Participants aged 65-75 years
Number of subjects: 13946

Group type: EXPERIMENTAL
Intervention: Participants with BMI ≥ 25 kg/m²
Number of subjects: 13946

Group type: EXPERIMENTAL
Intervention: Participants with antihypertensive treatment
Number of subjects: 13946

Group type: EXPERIMENTAL
Intervention: Residents inland
Number of subjects: 13946

Group type: EXPERIMENTAL
Intervention: Participants with moderate physical activity
Number of subjects: 13946

Group type: EXPERIMENTAL
Intervention: Participants with high physical activity
Number of subjects: 13946

Group type: EXPERIMENTAL
Intervention: Participants with glomerular filtration rate 60-90 ml/min per 1.73 m²
Number of subjects: 13946

Group type: EXPERIMENTAL
Intervention: Participants with glomerular filtration rate < 60 ml/min per 1.73 m²
Number of subjects: 13946

Group type: EXPERIMENTAL
Intervention: Participants with CT genotype at MTHFR 677C>T polymorphism
Number of subjects: 13946

Group type: EXPERIMENTAL
Intervention: Participants with TT genotype at MTHFR 677C>T polymorphism
Number of subjects: 13946

Group type: EXPERIMENTAL
Intervention: Smokers (men)
Number of subjects: 13946

Group type: EXPERIMENTAL
Intervention: Smokers (women)
Number of subjects: 13946

Group type: EXPERIMENTAL
Intervention: Males with hypertension grade 3
Number of subjects: 13946

Group type: EXPERIMENTAL
Intervention: Male non-drinkers
Number of subjects: 13946
Study: 21663813

Group type: EXPERIMENTAL
Intervention: Landiolol (0.125 mg/kg/min for one minute and then 0.04 mg/kg/min)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 42
Study: 19634511

Group type: EXPERIMENTAL
Intervention: Test formulation of clopidogrel
Number of subjects: 48

Group type: COMPARATOR
Intervention: Reference formulation of clopidogrel
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 48
Study: 16702890

Group type: EXPERIMENTAL
Intervention: Venlafaxine ER (37.5-300 mg/d)
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: Sertraline (25-200 mg/d)
Number of subjects: 538

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: Venlafaxine ER
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 538
Study: 15150566

Group type: EXPERIMENTAL
Intervention: Ultraflex stent placement
Number of subjects: 209

Group type: COMPARATOR
Intervention: Single-dose brachytherapy (12 Gy)
Number of subjects: 209
Study: 11004862

Group type: EXPERIMENTAL
Intervention: O‐OSA group (n = 35)
Number of subjects: 73

Group type: COMPARATOR
Intervention: BO‐OSA group (n = 14)
Number of subjects: 73

Group type: COMPARATOR
Intervention: O‐Z group (n = 24)
Number of subjects: 73
Study: 9232360

Group type: EXPERIMENTAL
Intervention: Fasted state during exercise
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Fed state during exercise
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Resting SMA blood flow (fed)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Resting forearm and leg blood flow (FBF and LBF) and vascular resistance (FVR and LVR)
Number of subjects: 10
Study: 8450402

Group type: EXPERIMENTAL
Intervention: beta-carotene, 180 mg/day
Number of subjects: 21

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 21
Study: 3922052

Group type: EXPERIMENTAL
Intervention: Nitroglycerin ointment (30 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate ointment (100 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31232639

Group type: EXPERIMENTAL
Intervention: SIT (sprint interval training) - twice‐weekly all‐out effort cycle sprints consisting of 6 × 10 s sprint with 80 s recovery
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group - maintained training
Number of subjects: 13
Study: 29310617

Group type: EXPERIMENTAL
Intervention: Exercise group (n=36): 3 weekly sessions of 35 min moderate intensity walking/running followed by 25 min resistance training
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (n=34): Standard maternal care
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 91
Study: 26704739

Group type: EXPERIMENTAL
Intervention: High dose condition
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: High plasma drug levels
Number of subjects: 73

Group type: COMPARATOR
Intervention: Treatment as usual control sample (n = 128)
Number of subjects: 73
Study: 24907875

Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg, 2 mL)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (0.9% saline, 2 mL)
Number of subjects: 20
Study: 22095647

Group type: COMPARATOR
Intervention: Plasma Exchange (PE)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Immunoadsorption (IA)
Number of subjects: 19
Study: 19185287

Group type: EXPERIMENTAL
Intervention: Etanercept (25 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 17365530

Group type: EXPERIMENTAL
Intervention: Intermittent hypoxic training group
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 22
Study: 15389189

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream
Number of subjects: 286

Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 286
Study: 11555831

Group type: COMPARATOR
Intervention: Control (healthy subjects)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diabetics (all groups)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diabetics (progression of nephropathy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diabetics with advanced nephropathy
Number of subjects: 0
Study: 9627171

Group type: EXPERIMENTAL
Intervention: Laparoscopic resection
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional resection
Number of subjects: 60
Study: 8179131

Group type: EXPERIMENTAL
Intervention: Pancuronium 0.2 mg.kg‐1
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Pipecuronium 0.2 mg.kg‐1
Number of subjects: 16
Study: 2979235

Group type: EXPERIMENTAL
Intervention: Enprostil (70 micrograms)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 6113682

Group type: EXPERIMENTAL
Intervention: 10 mg pirenzepine
Number of subjects: 6

Group type: COMPARATOR
Intervention: 2 ml saline (control)
Number of subjects: 6
Study: 31566239

Group type: EXPERIMENTAL
Intervention: Current tobacco users (66.5% of participants)
Number of subjects: 352

Group type: COMPARATOR
Intervention: Nonusers of tobacco
Number of subjects: 352
Study: 31800817

Group type: EXPERIMENTAL
Intervention: Auricular acupressure intervention with crystal pellets applied to six acupoints (shen men, kidney, stomach, cardia, brainstem, and endocrine) for 12 weeks
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 54
Study: 27819460

Group type: EXPERIMENTAL
Intervention: UV4.me (experimental website)
Number of subjects: 965
Study: 25934175

Group type: EXPERIMENTAL
Intervention: Interpersonal Community Psychiatric Treatment (ICPT)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Care As Usual (CAU)
Number of subjects: 180
Study: 23357152

Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose (FCM, 500-1000 mg as single shot infusion over 20 min)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ferric Gluconate (FG, 62.5 mg once weekly)
Number of subjects: 50
Study: 22022915

Group type: EXPERIMENTAL
Intervention: Peer reflection meeting
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standard feedback strategy without peer reflection
Number of subjects: 54
Study: 19542102

Group type: EXPERIMENTAL
Intervention: Airway Scope
Number of subjects: 70

Group type: COMPARATOR
Intervention: GlideScope
Number of subjects: 70
Study: 17521392

Group type: EXPERIMENTAL
Intervention: Astaxanthin 40 mg daily
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 15496219

Group type: EXPERIMENTAL
Intervention: 5 mg donepezil (single dose)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 5 mg donepezil (multiple doses for 23 days)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Healthy controls (5 mg donepezil, single dose)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Healthy controls (5 mg donepezil, multiple doses for 23 days)
Number of subjects: 36
Study: 11239307

Group type: EXPERIMENTAL
Intervention: Cycle ergometer aerobic training
Number of subjects: 157

Group type: COMPARATOR
Intervention: Relaxation training (control)
Number of subjects: 157
Study: 9609589

Group type: EXPERIMENTAL
Intervention: Unopposed estrogen replacement therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin hormone replacement therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Progestin addition to estrogen therapy
Number of subjects: 0
Study: 7816793

Group type: EXPERIMENTAL
Intervention: Tolfenamic acid (200 mg t.i.d.)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Mefenamic acid (500 mg t.i.d.)
Number of subjects: 73
Study: 3150019

Group type: EXPERIMENTAL
Intervention: MMC + FT + PSK
Number of subjects: 579
Study: 5337269

Group type: EXPERIMENTAL
Intervention: Treatment A (green and yellow gelatin capsule filled with lactose)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Treatment B (red and white capsule containing lactose)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (untreated subjects received a drink of water)
Number of subjects: 48
Study: 30566941

Group type: EXPERIMENTAL
Intervention: Ruxolitinib 20 mg twice daily
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 75
Study: 29091283

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Hepatic resection
Number of subjects: 218
Study: 24550168

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 2.5 mg/week
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 5 mg/week
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 10 mg/week
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 20 mg/week
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 395
Study: 24078507

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 117

Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 117
Study: 21723176

Group type: EXPERIMENTAL
Intervention: Educational group intervention (four educative workshops led by nurses over one year)
Number of subjects: 2127

Group type: COMPARATOR
Intervention: Control group (individual care)
Number of subjects: 2127
Study: 19128722

Group type: EXPERIMENTAL
Intervention: Locally injected ketorolac
Number of subjects: 140

Group type: COMPARATOR
Intervention: Intramuscularly injected ketorolac
Number of subjects: 140

Group type: COMPARATOR
Intervention: Local anesthetic alone
Number of subjects: 140

Group type: COMPARATOR
Intervention: No ketorolac
Number of subjects: 140
Study: 17915147

Group type: EXPERIMENTAL
Intervention: Educational intervention in home care unit for up to 15 days after hospital discharge.
Number of subjects: 279

Group type: COMPARATOR
Intervention: Control group (standard care).
Number of subjects: 279